Underrepresentation of female subjects in BE study to register Generic [Regulatives / Guidelines]

posted by ping4santosh  – India, 2020-03-11 16:37 (1504 d 11:30 ago) – Posting: # 21253
Views: 4,544

❝ Where do you intend to submit your data ? USA: the FDA wants males and females. Europe: EMA accepts studies in males only, but "we fear that we may fail if we include females" will not be an acceptable rationale.


Dear Ohlbe,

Thanks you your response. The pilot was not powered. Pivotal is powered given the high ISCV. We didn't pre-plan it in the pilot. We took M:Fe in the ratio of 2:1 and this is a post hoc analysis. We saw high ISCV and lower Cmax in Females as compared to Males. We intend to submit the data in EU but I won't be surprised if the management decides to submit that data in FDA at a later date.

Should you suggest me to go ahead with same M:Fe::2:1 ratio for a powered pivotal?

Cheers, SKM

Complete thread:

UA Flag
Activity
 Admin contact
22,993 posts in 4,828 threads, 1,657 registered users;
60 visitors (0 registered, 60 guests [including 7 identified bots]).
Forum time: 05:07 CEST (Europe/Vienna)

So far as I can remember,
there is not one word in the Gospels
in praise of intelligence.    Bertrand Russell

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5